Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season.

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-02-01 DOI:10.2807/1560-7917.ES.2025.30.6.2500040

Roberto Pastor-Barriuso, Olivier Núñez, Susana Monge

引用次数: 0

Abstract

Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77-108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35-50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.